Detail of "162359-56-0"

CAS Number:
162359-56-0
Name:
1,3-Propanediol,2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride (1:1)
Superlist Name:
Fingolimod hydrochloride
Molecular Structure:
Formula:
C₁₉H₃₄ClNO₂
Molecular Weight:
343.93
Synonyms:
1,3-Propanediol,2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride (9CI);2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diolhydrochloride;FTY 720;Fingolimod HCl;
Melting Point:
102-107 °C
Boiling Point:
479.5 °C at 760 mmHg
Flash Point:
243.8 °C
Appearance:
white solid

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Reference

FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease: All Rights Reserved. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. Hashimoto, Daigo; Asakura, Shoji; Matsuoka, Ken-ichi; Sakoda, Yukimi; Koyama, Motoko; Aoyama, Kazutoshi; Tanimoto, Mitsune; Teshima, Takanori (Biopathological Science, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan). European Journal of Immunology, 37(1), 271-281 (English) 2007 Wiley-VCH Verlag GmbH & Co. KGaA. CODEN: EJIMAF. ISSN: 0014-2980. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) FTY720 is a novel immunosuppressant that improves the outcomes after solid organ and bone marrow transplantation (BMT) due to the sequestration of T cells into LN.In this article, certain chemicals are used. One of their cas registry numbers is 162359-56-0 We tested the hypothesis that the sequestration of donor T cells in LN by FTY720 would enhance their interaction with host APC, thus causing a greater degree of activation-induced apoptosis of alloreactive T cells, and thereby resulting in a redn. of graft-vs.-host disease (GVHD). The short-term administration of FTY720 improved the recipient survival after allogeneic BMT. FTY720 treatment facilitated a rapid contraction of the donor T cell pool in assocn. with an increased degree of apoptosis of donor T cells. The donor T cell reactivity to host alloantigens was diminished in host's LN and adoptive transfer of donor T cells isolated from LN of FTY720-treated recipients of allogeneic BMT induced less severe GVHD in secondary recipients than the transfer from controls. Caspase-dependent apoptosis was involved in this mechanism because FTY720-induced protection was abrogated when a pan-caspase inhibitor was administered. These findings thus demonstrate the presence of a novel mechanism by which FTY720 modulates the allogeneic T cell responses: namely, by the induction of activation-induced apoptosis of alloreactive T cells in LN. .

Regulation of Donor T Cells in the Tolerant Rats to Graft-Versus-Host Disease by FTY720 Following Small Bowel Transplantation: All Rights Reserved. Regulation of Donor T Cells in the Tolerant Rats to Graft-Versus-Host Disease by FTY720 Following Small Bowel Transplantation. Song, J.; Ito, T.; Matsuda, C.; Tanemura, M.; Nishida, T.; Nozawa, M.; Sawa, Y. (Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan). Transplantation Proceedings, 38(10), 3181-3183 (English) 2006 Elsevier Inc. CODEN: TRPPA8. ISSN: 0041-1345. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Aims: The potency of immunosuppression is a crit. factor in small bowel transplantation (SBTx). FTY720 altered lymphocyte trafficking and prevented the donor T cells from migrating into target organs, resulting in the prolongation of recipient survival in acute graft-vs.-host disease (GVHD) of SBTx. However, the effect of FTY720 on donor T cells in the chronic phase of GVHD following SBTx remains unclear. Methods: Heterotopic SBTx was performed in a WF-to-F1 (WF ′ ACI) rat combination. Recipients were given FTY720 for 14 days after SBTx. The subpopulations of donor-derived T cells and the cytokine prodn. in the target tissues were evaluated on postoperative day 150. Results: FTY720 treatment significantly prolonged recipient survival over 150 days without any clin. signs of GVHD. The nos. of donor-derived CD4+ and CD8+ T cells in the peripheral blood, mesenteric lymph nodes, and Peyer's patches of recipients were maintained at low levels on postoperative 150, which were almost similar to the levels on postoperative day 14. In the host lamina propria, however, a significant higher no. of donor T cells (CD4+, 18.4 ± 4. 162359-56-0 which is the cas registry number of some chemical is mentioned.3 ′ 104; CD8+, 13.9 ± 3.6 ′ 104) were still obsd. on postoperative day 150. Prodn. of interferon-g was significantly reduced in target tissues by FTY720 treatment both in the acute and chronic phase. However, interleukin-4 and interleukin-10 prodn., which was significantly higher on day 14, returned to the level of naive rats in the chronic phase. Conclusions: A 14-day treatment of FTY720 induced tolerance in our SBTx model. Down-regulation of both Th1 and Th2 immune response was obsd. in the chronic phase. .

Detail of "162359-56-0"

1,3-Propanediol,2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride (1:1)

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod Hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

CAS No.162359-56-0 Fingolimod hydrochloride

Reference